Opioid use remits, depression remains

Sajoy P. Varghese, MD, Maju Mathew Koola, MD, DPM, Rodney I. Eiger, MD, and Maria Devens, PhD, ABPP†

Mr. B, age 55, has been depressed since adolescence and is addicted to opioids. Pharmacotherapy helped, but symptoms returned and he reports memory loss. How would you treat him?

**CASE** Forgetful and depressed

Mr. B, age 55, has been a patient at our clinic for 8 years, where he has been under our care for treatment-resistant depression and opioid addiction [read about earlier events in his case in “A life of drugs and ‘downtime’” CURRENT PSYCHIATRY, August 2007, p. 98-103]. He reports feeling intermittently depressed since his teens and has had 3 near-fatal suicide attempts.

Three years ago, Mr. B reported severe depressive symptoms and short-term memory loss, which undermined his job performance and contributed to interpersonal conflict with his wife. The episode has been continuously severe for 10 months. He was taking sertraline, 150 mg/d, and duloxetine, 60 mg/d, for major depressive disorder (MDD) and sublingual buprenorphine/naloxone, 20 mg/d, for opioid dependence, which was in sustained full remission. Mr. B scored 24/30 in the Mini-Mental State Examination, indicating mild cognitive deficit. Negative results of a complete routine laboratory workup rule out an organic cause for his deteriorating cognition.

**How would you diagnose Mr. B’s condition at this point?**

- a) treatment-resistant MDD
- b) cognitive disorder not otherwise specified
- c) opioid use disorder
- d) a and c

**The authors’ observations**

Relapse is a core feature of substance use disorders (SUDs) that contributes significantly to the longstanding functional impairment in patients with a mood disorder. With the relapse rate following substance use treatment estimated at more than 60%, SUDs often are described as chronic relapsing conditions. In chronic stress, corticotropin-releasing factor (CRF) is over-sensitized; we believe that acute stress can cause an unhealthy response to an over-expressed CRF system.

To prevent relapse in patients with an over-expressed CRF system, it is crucial to manage stress. One treatment option to consider in preventing relapse is mindfulness-based interventions (MBI). Mindfulness has been described as “paying attention in...”
a particular way: on purpose, in the present moment, and non-judgmentally.” In the event of a relapse, awareness and acceptance fostered by mindfulness may aid in recognizing and minimizing unhealthy responses, such as negative thinking that can increase the risk of relapse.

**HISTORY** Remission, then relapse

Mr. B was admitted to inpatient psychiatric unit after a near-fatal suicide attempt 8 years ago and given a diagnosis of MDD recurrent, severe without psychotic features. Trials of sertraline, buproprion, trazodone, quetiapine, and aripiprazole were ineffective.

Before he presented to our clinic 8 years ago, Mr. B had been taking venlafaxine, 75 mg/d, and mirtazapine, 30 mg at bedtime. His previous outpatient psychiatrist added methylphenidate, 40 mg/d, to augment the antidepressants, but this did not alleviate Mr. B’s depression.

At age 40, he entered a methadone program, began working steadily, and got married. Five years later, he stopped methadone (it is unclear from the chart if his psychiatrist initiated this change). Mr. B’s depression persisted while using opioids and became worse after stopping methadone.

We considered electroconvulsive therapy (ECT) at the time, but switching the antidepressant or starting ECT would address only the persistent depression; buprenorphine/naloxone would target opioid craving. We started a trial of buprenorphine/naloxone, a partial µ opioid agonist and κ opioid antagonist; κ receptor antagonism serves as an antidepressant. He responded well to augmentation of his current regimen (mirtazapine, 30 mg at bedtime, and venlafaxine, 225 mg/d) with buprenorphine/naloxone, 16 mg/d. He reported no anergia and said he felt more motivated and productive.

Mr. B took buprenorphine/naloxone, 32 mg/d, for 4 years until, because of concern for daytime sedation, his outpatient psychiatrist reduced the dose to 20 mg/d. With the lower dosage of buprenorphine/naloxone initiated 4 years ago, Mr. B reported irritability, anhedonia, insomnia, increased self-criticism, and decreased self-care.

**How would you treat Mr. B’s depression at this point?**

a) switch to a daytime antidepressant  
b) adjust the dosage of buprenorphine/naloxone  
c) try ECT  
d) try mindfulness-based cognitive therapy

**The authors’ observations**

Mindfulness meditation (MM) is a meditation practice that cultivates awareness. While learning MM, the practitioner intentionally focuses on awareness—a way of purposely paying attention to the present moment, non-judgmentally, to nurture calmness and self-acceptance. Being conscious of what the practitioner is doing while he is doing it is the core of mindfulness practice.

**Mindfulness-based interventions.** We recommended the following forms of MBI to treat Mr. B:

- Mindfulness-based cognitive therapy (MBCT). MBCT is designed to help people who suffer repeated bouts of depression and chronic unhappiness. It combines the ideas of cognitive-behavioral therapy (CBT) with MM practices and attitudes based on cultivating mindfulness.
- Mindfulness-based stress reduction (MBSR). MBSR brings together MM and physical/breathing exercises to relax body and mind.

**Chronic stress and drug addiction**

The literature demonstrates a significant association between acute and chronic stress and motivation to abuse substances. Stress mobilizes the CRF system to stimulate the hypothalamic-pituitary-adrenal (HPA) axis, and extra-hypothalamic actions of CRF can kindle the neuronal circuits responsible for...
stress-induced anxiety, dysphoria, and drug abuse behaviors. A study to evaluate effects of mindfulness on young adult romantic partners' HPA responses to conflict stress showed that MM has sex-specific effects on neuroendocrine response to interpersonal stress. Research has shown that MM practice can decrease stress, increase well-being, and affect brain structure and function. Meta-analysis of studies of animal models and humans described how specific interventions intended to encourage pro-social behavior and well-being might produce plasticity-related changes in the brain. This work concluded that, by taking responsibility for the mind and the brain by participating in regular mental exercise, plastic changes in the brain promoted could produce lasting beneficial consequences for social and emotional behavior.

What could be perpetuating Mr. B's depression?
1) psychosocial stressors
2) over-expression of CRF gene due to psychosocial stressors
3) a and b

**TREATMENT** Mindfulness practice

Mr. B was started on CBT to manage anxiety symptoms and cognitive distortions. After 2 months, he reports no improvements in anxiety, depression, or cognitive distortions.

We consider MBI for Mr. B, which was developed by Segal et al to help prevent relapse of depression and gain the benefits of MM. There is evidence that MBI can prevent relapse of SUDs. Mr. B's MBI practice is based on MBCT, as outlined by Segal et al. He attends biweekly, 45-minute therapy sessions at our outpatient clinic. During these sessions, MM is practiced for 10 minutes under a psychiatrist's supervision.
The MBCT manual calls for 45 minutes of MM practice but, during the 10-minute session, we instruct Mr. B to independently practice MM at home. Mr. B is assessed for relapses, and drug cravings; a urine toxicology screen is performed every 6 months.

We score Mr. B's day-to-day level of mindfulness experience, depression, and anxiety symptoms before starting MBI and after 8 weeks of practicing MBI (Figure 1, page 47). Mindfulness is scored with the Mindful Attention Awareness Scale (MAAS), a valid, reliable scale. The MAAS comprises 15 items designed to reflect mindfulness in everyday experiences, including awareness and attention to thoughts, emotions, actions, and physical states. Items are rated on a 6-point Likert-type scale of 1 (“almost never”) to 6 (“almost always”). A typical item on MAAS is “I find myself doing things without paying attention.”

Depression and anxiety symptoms are measured using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Scale-7 (GAD-7) Item Scale. Mr. B scores a 23 on PHQ-9, indicating severe depression (he reports that he finds it “extremely difficult” to function) (Figure 2). There is evidence to support the use of PHQ-9 for measurement-based care in the psychiatric population. PHQ-9 does not capture anxiety, which is a strong predictor of suicidal behavior; therefore, we use GAD-7 to measure the severity of Mr. B’s subjective anxiety. He scores a 14 on GAD-7 and reports that it is “very difficult” for him to function.

Mr. B is retested after 8 weeks. During those 8 weeks, he was instructed by audio guidance in body scan technique. He practices MBI techniques for 45 minutes every morning between 5 AM and 6 AM.

Clinical Point

Mr. B’s CRF may have been down-regulated by MBI, which in turn decreased his depressive and anxiety symptoms.

Mindfulness-based intervention decreased symptoms of depression and anxiety

Shown are Mr. B’s Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Scale-7 Item Scale (GAD-7) scores. At baseline, PHQ-9 was 23, suggesting severe depression. PHQ-9 score declined to 14 (moderate depression) 2 months later and, 8 months later, to 2 (remission). He scored 14 (severe anxiety) at baseline on GAD-7, which declined to 7 (moderate anxiety) at 2 months and 2 (minimal anxiety) at 8 months, suggesting that anxiety symptoms diminished as he practiced mindfulness-based interventions.
After 3 months of MBI, Mr. B is promoted at work and reports that he is handling more responsibilities. He is stressed at his new job and, subsequently, experiences a relapse of anxiety symptoms and insomnia. Partly, this is because Mr. B is not able to consistently practice MBI and misses a few outpatient appointments. In the meantime, he has difficulties with sleep and concentration and anxiety symptoms.

The treating psychiatrist reassures Mr. B and provides support to restart MBI. He manages to attend outpatient clinic appointments consistently and shows interest in practicing MBI daily. Later, he reports practicing MBI consistently along with his routine treatment at our clinic. The timeline of Mr. B’s history and treatment are summarized in Figure 3.

The authors’ observations

Mr. B’s CRF may have been down-regulated by MBI. This, in turn, decreased his depressive and anxiety symptoms, thereby helping to prevent relapse of depression and substance abuse. He benefited from MBI practices in several areas of his life, which can be described with the acronym FACES.10

Flexible. Mr. B became more cognitively flexible. He started to realize that “thoughts are not facts.” This change was reflected in his relationship with his wife. His wife came to one of our sessions because she noticed significant change in his attitude toward her. Their marriage of 15 years was riddled with conflict and his wife was excited to see the improvement he achieved within the short time of practicing MBI.

Adaptive. He became more adaptive to changes at the work place and reported that he is enjoying his work. This is a change from his feeling that his job was a burden, as he observed in our earlier sessions.

Bottom Line

Mindfulness-based interventions provide patients with tools to target symptoms such as poor affect regulation, poor impulse control, and rumination. Evidence supports that using MBI in addition to the usual treatment can prevent relapse of a substance use disorder.

Clinical Point

Mr. B became more cognitively rational and reported improvement in his memory and concentration

---

Figure 3
The narrative of Mr. B’s history and treatment

2006: Inpatient psychiatry refers Mr. B to the outpatient psychiatry clinic.
October 2006: Started buprenorphine/naloxone 8 mg/d, which was was increased to 16 mg/d. Mr. B responded to the augmentation therapy.

2010-2011: Increased buprenorphine/naloxone to 32 mg/d.
Because of the concern of daytime sedation buprenorphine/naloxone dose was reduced to 20 mg/d and subsequently Mr. B’s depression worsened.

July-August 2011: Mr. B’s care is transferred to a new psychiatrist.
November 2011-May 2012: Patient achieved remission with the help of consistent MBI practice.

2006: Inpatient psychiatry refers Mr. B to the outpatient psychiatry clinic.

2010-2011: Increased buprenorphine/naloxone to 32 mg/d.
Because of the concern of daytime sedation buprenorphine/naloxone dose was reduced to 20 mg/d and subsequently Mr. B’s depression worsened.

July-August 2011: Mr. B’s care is transferred to a new psychiatrist.
November 2011-May 2012: Patient achieved remission with the help of consistent MBI practice.
As Mr. B became more emotionally stable by practicing MBI, he did not have the urge to use drugs and he did not relapse.

Coherent. He became more cognitively rational. He reported improvement in his memory and concentration. Five months after initiation of MBI and MM training, he was promoted and could cope with the stress at work.

Energized. Initially, he had said that he never wanted to be part of his extended family. During a session toward the end of the treatment, he mentioned that he made an effort to contact his extended family and reported that he found it more meaningful now to be reconnected with them.

Stable. He became more emotionally stable. He did not have the urge to use drugs and he did not relapse.

As we hypothesized, for Mr. B, practicing MBI was associated with abstinence from substance use, increased mindfulness, acceptance of mental health problems, and remission of psychiatric symptoms.

References